Purgatory is hell with hope.”
- Philip José Farmer
Today we take an in-depth look at this "Tier 4" biotech concern and "Busted IPO". The company recently inked a developmental deal with Alexion Pharmaceuticals (ALXN), which buoyed the beaten-down shares following the announcement.
Company Overview
Stealth BioTherapeutics (MITO) is a Cayman Islands clinical-stage biotechnology concern focused on the development of therapies that address diseases involving mitochondrial dysfunction. The company was founded in 2006 and conducts its operations through Stealth Delaware, headquartered in Newton, Massachusetts. Stealth went public